Development of a screening system for agents that modulate taste receptor expression with the CRISPR-Cas9 system in medaka

Beppu, Kana; Tsutsumi, Rie; Ansai, Satoshi; Ochiai, Nana; Terakawa, Mai; Mori, Marie; Kuroda, Masashi; Horikawa, Kazuki; Tomoi, Takumi; Sakamoto, Joe; Kamei, Yasuhiro; Naruse, Kiyoshi; Sakaue, Hiroshi

doi:10.1016/j.bbrc.2022.02.082

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human gene editing is regulated by strict ethical norms and currently undergoes scientific, philosophical, and political discussion [ 22 , 23 ]; however, in principle, it is executable. Besides the mammals, also genome of reptiles [ 24 ], amphibians ( Xenopus laevis and X. tropicalis ) [ 25 , 26 ], fish ( Danio rerio , Oryzias latipes ) [ 26 – 28 ], insects ( Drosophila melanogaster , mosquitoes) [ 29 , 30 ], worms ( Caenorhabditis elegans ) [ 31 , 32 ], plants [ 33 – 35 ], fungi [ 36 , 37 ], bacteria [ 38 ], and viruses [ 39 ] can be edited by CRISPR/Cas9. Paradoxically, using the CRISPR/Cas9 technology is not as common in bacteria as in other organisms, likely because other methods based on homologous recombination were already available for efficient manipulation of their genomes [ 40 ].…”

Section: Technological Innovation By the Crispr/cas Gene Editingmentioning

confidence: 99%

Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine

et al. 2023

View full text Add to dashboard Cite

Since 2009, the European Association for Predictive, Preventive and Personalised Medicine (EPMA, Brussels) promotes the paradigm change from reactive approach to predictive, preventive, and personalized medicine (PPPM/3PM) to protect individuals in sub-optimal health conditions from the health-to-disease transition, to increase life-quality of the affected patient cohorts improving, therefore, ethical standards and cost-efficacy of healthcare to great benefits of the society at large. The gene-editing technology utilizing CRISPR/Cas gene-editing approach has demonstrated its enormous value as a powerful tool in a broad spectrum of bio/medical research areas. Further, CRISPR/Cas gene-editing system is considered applicable to primary and secondary healthcare, in order to prevent disease spread and to treat clinically manifested disorders, involving diagnostics of SARS-Cov-2 infection and experimental treatment of COVID-19. Although the principle of the proposed gene editing is simple and elegant, there are a lot of technological challenges and ethical considerations to be solved prior to its broadly scaled clinical implementation. This article highlights technological innovation beyond the state of the art, exemplifies current achievements, discusses unsolved technological and ethical problems, and provides clinically relevant outlook in the framework of 3PM.

show abstract